glp-1 obesity drug news today september 2025 25 GLP-1 Agonists Market Report 2025-2033 Lilly and Novo finalize GLP-1

W.PhilipsonL

The legitimate medical uses of intravenous infusions may not need a Therapeutic Use Exemption in certain settings (hospital treatment, surgical procedures or clinical investigations)

This has been achieved through techniques such as peptide sequence modification, peptide lipidation, albumin fusion, and Fc fusion

The benefits of using semaglutide GLP-1 for weight loss are significant

Most RCTs failed to demonstrate a significant association between GLP-1 RAs and the occurrence of pancreatitis or pancreatic cancer, primarily because of their short duration and insufficient design for evaluating such risks